Home
Post
Share
@CovidAnalysis
Meta AnalysisMeta
Variants may be resistant to ensitrelvir Lopez.
Recent:Lopez.
Ensitrelvir was adopted
in 1 country.
Submit updates/corrections .
Summary.
Dec 23 |
Ensitrelvir for COVID-19: real-time meta analysis of 3 studies | |
| Significantly lower risk is seen for viral clearance. 3 studies from 2 independent teams (all from the same country) show significant benefit. Meta analysis using the most serious outcome reported shows 26% [-14‑52%] lower risk.. | ||
Aug 12 |
et al., The Journal of Infectious Diseases, doi:10.1093/infdis/jiae385 | Persistence of an infectious form of SARS-CoV-2 post protease inhibitor treatment of permissive cells in vitro |
| In Vitro study showing the persistence of an infectious form of SARS-CoV-2 after treatment with 3CLpro inhibitors nirmatrelvir and ensitrelvir, which may explain the rebound often seen with paxlovid. 3CLpro is crucial for processing viral.. | ||
Jul 6 |
et al., Quantitative Biology, doi:10.1002/qub2.60 | Assessing the inhibition efficacy of clinical drugs against the main proteases of SARS‐CoV‐2 variants and other coronaviruses |
| In Vitro study showing that leritrelvir and GC376 remained effective against some nirmatrelvir- and ensitrelvir-resistant Mpro mutants. Leritrelvir showed better broad-spectrum activity against other pathogenic coronaviruses compared to e.. | ||
Jun 24 |
et al., Current Clinical Microbiology Reports, doi:10.1007/s40588-024-00229-6 | SARS-CoV-2 Resistance to Small Molecule Inhibitors |
| Review of resistance mutations in SARS-CoV-2 3CLpro and nsp12 that could reduce efficacy of antiviral therapies including nirmatrelvir, ensitrelvir, remdesivir, and favipiravir. Authors identify 39 single mutations across 17 critical resi.. | ||
Feb 29 |
et al., Antiviral Research, doi:10.1016/j.antiviral.2024.105852 | Prophylactic effect of ensitrelvir in mice infected with SARS-CoV-2 |
| Mouse study showing protective effects against SARS-CoV-2 infection in aged mice with the 3CL protease inhibitor ensitrelvir. A single subcutaneous dose of ensitrelvir at 64, 96, or 128 mg/kg given 24 hours before a lethal SARS-CoV-2 chal.. | ||
Feb 6 |
et al., Cureus, doi:10.7759/cureus.61048 (date from preprint) | Real-World Efficacy of Ensitrelvir in Hospitalized Patients With COVID-19 in Japan: A Retrospective Observational Study |
| Retrospective 154 hospitalized COVID-19 patients in Japan showing faster viral clearance and shorter hospitalization with ensitrelvir treatment compared to remdesivir or molnupiravir. There was no significant difference for fever resoluti.. | ||
Dec 31 2023 |
, E., Aging and disease, doi:10.14336/AD.2023.0318 | Mitigating COVID-19 Mortality and Morbidity in China's Aging Population: A Focus on Available Medications and Future Developments |
| Review focusing on 3CL protease inhibitors. First generation inhibitors like paxlovid and simnotrelvir require boosting with ritonavir, which can cause drug-drug interactions and other issues. Second generation inhibitors like ensitrelvir.. | ||
Nov 30 2023 |
et al., iScience, doi:10.1016/j.isci.2023.108147 | Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate |
| In Vitro and animal study showing that the SARS-CoV-2 omicron subvariant XBB.1.9.1 has similar antigenicity, antiviral susceptibility, and replicative ability compared to XBB.1.5. Casirivimab, imdevimab, tixagevimab, cilgavimab, sotrovima.. | ||
Jul 13 2023 |
et al., JAMA Network Open, doi:10.1001/jamanetworkopen.2023.54991 (date from preprint) | Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19: The SCORPIO-SR Randomized Clinical Trial |
| 11% faster recovery (p=0.3) and 49% improved viral clearance (p=0.001). RCT 1,821 COVID-19 outpatients in Japan, Vietnam, and South Korea, showing improved viral clearance and improved recovery (significant for patients treated within 3 days of onset) with ensitrelvir. Only 2 hospitalizations were reported, w.. | ||
Feb 10 2023 |
et al., Journal of Antimicrobial Chemotherapy, doi:10.1093/jac/dkad027 | Efficacy comparison of 3CL protease inhibitors ensitrelvir and nirmatrelvir against SARS-CoV-2 in vitro and in vivo |
| In Vitro and animal study comparing nirmatrelvir and ensitrelvir, showing similar efficacy in vitro, and equal or better efficacy of ensitrelvir in vivo (with similar unbound-drug plasma concentrations). | ||
Dec 7 2022 |
et al., Clinical Infectious Diseases, doi:10.1093/cid/ciac933 | Efficacy and safety of ensitrelvir in patients with mild-to-moderate COVID-19: the phase 2b part of a randomized, placebo-controlled, phase 2/3 study |
| 9% improved recovery (p=0.28) and 32% faster viral clearance (p=0.0001). RCT 428 COVID-19 patients in Japan showing faster viral clearance and improved recovery with ensitrelvir. | ||
May 17 2022 |
et al., medRxiv, doi:10.1101/2022.05.17.22275027 | A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-like Protease Inhibitor, in Japanese Patients With Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part |
| 45% improved viral clearance (p=0.002). RCT 69 patients in in Japan, showing faster viral clearance with ensitrelvir. 5-day ensitrelvir (375mg on day 1 followed by 125 mg daily or 750mg on day 1 followed by 250mg daily). | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 100,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.